References
- Guan Z, Zhang X, Ravid R. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer’s disease. J Neurochem 2000;74:237–43
- Nordberg A. Nicotinic receptor abnormalities of Alzheimer’s disease: therapeutic implications. Biol Psychiatry 2001;49:200–10
- Shinotoh H, Namba H, Fukushi K, et al. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer’s disease: a positron emission tomography study. Ann Neurol 2000;48:194–200
- Perry EK, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease: possible index of early neuropathology. Neuroscience 1995;64:385–95
- Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry 2001;49:279–88
- Bores GM, Huger FP, Petko W, et al. Pharmacological evaluation of novel Alzheimer’s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996;277:728–38
- Bourin M, Ripoll N, Dailly E. Nicotinic receptors and Alzheimer’s disease. Curr Med Res Opin 2003;19:169–77
- Samochocki M, Zerlin M, Jostock R. Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 naChR. Acta Neurol Scand 2000;176(Suppl):68–73
- Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261–8
- Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269–76
- Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Br Med J 2000;321:1445–9
- Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589–95
- Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189–98
- Rosen W, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984;141:1356–64
- Schneider LS, Olin JT, Doody RS. Validity and reliability of the Alzheimer’s Disease Cooperative Study – clinical global impression of change. Alzheimer Dis Assoc Disord 1997;1 (Suppl 2):S22–S32
- Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. Am J Occup Ther 1999;53:471–81
- Galasko D, Bennett D, Sano M. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. The Alzheimer’s Disease Cooperative Society. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S33–S39
- Weyer G, Erzigkeit H, Kanowski S, et al. Alzheimer’s Disease Assessment Scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatrics 1997;9:123–38
- Burback D, Molnar FJ, St John P, et al. Key methodological features of randomized controlled trials of Alzheimer’s disease therapy. Dement Geriatr Cogn Disord 1999;10:534–40
- Doraiswamy PM, Kaiser L, Bieber F, et al. The Alzheimer’s Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer’s disease. Alzheimer Dis Assoc Disord 2001;15:174–83
- Wilkinson DG, Hock C, Farlow M, et al. Galantamine provides broad benefits in patients with ‘advanced moderate’ Alzheimer’s disease (MMSE = 12) for up to six months. Int J Clinical Practice 2002;56:509–14
- Seltzer B, Zolnouni P, Nunez M, et al. Benefits of donepezil treatment in patients with very mild Alzheimer’s disease. Presented at 6th Congress of the European Federation of Neurological Societies (EFNS), October 26–29, 2002 Vienna.